文献速递食管胃疾病与幽门螺杆菌

十日伏诺拉生-阿莫西林双联疗法与标准十四日铋剂四联疗法用于幽门螺杆菌一线根除的多中心随机临床试验

Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
PubMed 文献 · Am J Gastroenterol · 2023-11-17

在中国东部3家机构开展前瞻性随机临床试验,314例未治疗幽门螺杆菌感染者1:1分为10日伏诺拉生-阿莫西林双联组与14日铋剂四联组。按意向治疗分析根除率分别为86.0%与89.2%(P=0.389),双联疗法非劣效于四联疗法;双联组不良事件发生率显著更低(P<0.001)。

要点

  • 10日伏诺拉生-阿莫西林双联疗法根除率非劣效于14日铋剂四联疗法。
  • 双联组不良事件发生率显著低于四联组(P<0.001)。
  • 双联组依从性差导致根除失败(P<0.001),四联组无此关联(P=0.110)。

核心结论

  • 10日伏诺拉生-阿莫西林双联疗法作为幽门螺杆菌一线治疗,根除率在符合方案分析中>90%,且不良事件发生率低于标准14日铋剂四联疗法。

研究设计与样本

  • 前瞻性随机临床试验,在中国东部3家机构开展,314例未治疗幽门螺杆菌感染患者按1:1随机分为10日伏诺拉生-阿莫西林双联组或14日铋剂四联组。

主要发现

  • 意向治疗分析根除率:双联组86.0% vs 四联组89.2%(P=0.389)。
  • 改良意向治疗分析根除率:双联组88.2% vs 四联组91.5%(P=0.338)。
  • 符合方案分析根除率:双联组90.8% vs 四联组91.3%(P=0.884)。
  • 双联组不良事件发生率显著低于四联组(P<0.001)。
  • 双联组依从性差导致根除失败(P<0.001),四联组无此关联(P=0.110)。

关键数值与推荐

  • 在所有意向治疗、改良意向治疗和符合方案分析中,双联疗法均非劣效于四联疗法。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Whether 10-day short-course vonoprazan-amoxicillin dual therapy (VA-dual) is noninferior to the standard 14-day bismuth-based quadruple therapy (B-quadruple) against Helicobacter pylori eradication has not been determined. This trial aimed to compare the eradication rate, adverse events, and compliance of 10-day VA-dual regimen with standard 14-day B-quadruple regimen as first-line H. pylori treatment. METHODS: This prospective randomized clinical trial was performed at 3 institutions in eastern China. A total of 314 treatment-naive, H. pylori -infected patients were randomly assigned in a 1:1 ratio to either 10-day VA-dual group or 14-day B-quadruple group. Eradication success was determined by 13 C-urea breath test at least 4 weeks after treatment. Eradication rates, adverse events, and compliance were compared between groups. RESULTS: Eradication rates of VA-dual and B-quadruple groups were 86.0% and 89.2% ( P = 0.389), respectively, by intention-to-treat (ITT) analysis; 88.2% and 91.5% ( P = 0.338), respectively, by modified ITT analysis; and 90.8% and 91.3% ( P = 0.884), respectively, by per-protocol (PP) analysis. The efficacy of the VA-dual remained noninferior to B-quadruple therapy in all ITT, modified ITT, and PP analyses. The incidence of adverse events in the VA-dual group was significantly lower compared with that in the B-quadruple group ( P < 0.001). Poor compliance contributed to eradication failure in the VA-dual group ( P < 0.001), while not in the B-quadruple group ( P = 0.110). DISCUSSION: The 10-day VA-dual therapy provided satisfactory eradication rates of >90% (PP analysis) and lower rates of adverse events compared with standard 14-day B-quadruple therapy as first-line H. pylori therapy. TRAIL REGISTRATION NUMBER: ChiCTR2300070100.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Yan TL, Wang JH, He XJ, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial. Am J Gastroenterol. 2023. PMID: 37975609. doi:10.14309/ajg.0000000000002592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。